Guillain-Barré Syndrome and Influenza Vaccine

James J. Sejvar, MD; Lawrence B. Schonberger, MD, MPH
Division of Viral and Rickettsial Diseases
National Center for Zoonotic, Vectorborne, and Enteric Diseases
Centers for Disease Control and Prevention

Dina Pfeifer, MD, MSc
Department of Immunization, Vaccines, and Biologicals
World Health Organization

Guillain-Barré Syndrome (GBS)

- Immune-mediated polyradiculoneuropathy
  - Acute – subacute “ascending” limb weakness with decreased reflexes
  - Cranial nerve palsies, respiratory failure
- Several potential mechanisms hypothesized
  - Humoral or cellular immune response to antigenic stimulus, resulting in attack on nerve self-proteins
  - Numerous infectious agents and immunizations temporally associated
  - Strongest association with Campylobacter jejuni infection – “molecular mimicry”
- Incidence increases with age, particularly over 50
- Characteristic clinical, laboratory, electrodiagnostic features
- Outcome generally favorable
  - Case fatality 5 – 10%
  - Neurologic sequelae in 20%
  - Older age with worse prognosis
GBS and Influenza Vaccine: Methods

- All available literature reviewed (limited to controlled studies)
- Use of swine-antigen containing influenza vaccines, including A/NJ/76 (H1N1), used pre- and post-1976 assessed
- Archived WHO, CDC, CBER records
  - AFEB records
  - Personal communications
- Comparison data on virologic, molecular characteristics of A/NJ/79 influenza virus, current A/CA/09 virus, other SW-OI viruses
- Best available data for “background” rates of GBS:
  - 1.0 – 1.7 / 100,000 population / year in developed countries
  - When possible, published rates converted to incidence / 100,000 for comparison

GBS and A/NJ/76 (H1N1) Vaccine

- 1976: human-to-human transmission of swine-origin H1N1 influenza virus on US military base
  - 40 million doses of vaccine among US civilians, military
  - Influenza epidemic never materialized
- “Cluster” of GBS cases noted though AE surveillance early in campaign
  - Campaign discontinued Dec. 16, 1976
- Subsequent assessment of US civilians by CDC, state health depts.
  - Active, national case-finding between December 16, 1976 and Jan 31, 1977
  - GBS among adult vaccinees compared to non-vaccinees (“expected” rate)
1. Based on 8 controlled assessments, A/NJ/76 (H1N1) influenza vaccine associated with increased risk of GBS in adults

- RR of 7.6 (95% CI 6.7 – 8.6)
- Reporting rate of 8.6 cases / 100,000 / yr
  - Non-vaccinees: 1.7 / 100,000 / yr
- Attributable risk of 0.95 / 100,000 vaccinees
- Features consistent with biological plausibility
  - Risk concentrated within first 6 weeks of vaccination (peak at week 2 – 3)
- Not a lot- or manufacturer- specific phenomenon
- Several re-analyses with same conclusions

2. There are limited data on GBS risk among other populations receiving vaccine.

- U.S. Military
  - A/NJ/76 formulation (bivalent) same as civilian, but higher dose (1.0 ml vs. 0.5 ml); also received B vaccine
  - Single study: “no increased risk of the magnitude reported by CDC”; limitations in data*
  - No additional controlled data
- Use of A/NJ/76 vaccine outside US
  - UK: ? Anecdotal reports, but no confirmation
  - Canada: 800,000 doses of monovalent and bivalent vaccine distributed
    - Limited mechanisms to detect risk of GBS; small population of vaccinees
  - Netherlands
    - 2.4 million doses apparently delivered
    - None apparently used

*Johnson, D. Arch Neurol 1982;39:21
3. There are limited data on risk of GBS from swine-antigen-containing influenza vaccines pre-1976

- 1956 – 1959: same antigen incorporated in some civilian vaccines
- No suggestion of increased risk
  - Limited passive surveillance infrastructure
  - No systematic assessments
  - In limited exposed population, no risk of sufficient concern enough to be reported to public health authorities or published
- Swine antigens not used since 1976 (Netherlands 1977?)

4. Most data suggest little, if any, significant risk of GBS following subsequent influenza vaccines

- Association between other influenza vaccine formulations and GBS less clear
- 9 well-designed, controlled assessments between 1977 and 2009
- Two suggesting a small but statistically significant increase in risk of GBS
  - Lasky et al*:
    - increased risk following influenza vaccine for combined 1992-93 and 1993-94 seasons (RR 1.7; 95% CI 1.0 – 2.4; AR 0.06 / 100,000 vaccinations);
    - no such risk with each season separately.
  - Juurlink et al#:
    - increased risk of GBS following presumed influenza vaccination over period of 1993 – 2004 (RR 1.45, 95% CI 1.05 – 1.99)
    - No increase in incidence of hospital admissions for GBS following universal influenza vaccination in Ontario in 2000.
- Differences in methodologies, case ascertainment methods, analyses
- No clear, consistent association
- Potential GBS risk likely outweighed by influenza-associated morbidity / mortality in any particular season

5. Biological data on possible mechanisms for association of GBS and A/NJ/76 (H1N1) vaccine are largely absent

- No association with particular human leukocyte antigen (HLA) haplotypes
- A/NJ/76 vaccine, but also other formulations, induces anti-myelin ganglioside antibodies in mice (Nachamkin et al. 2008)
  - Provides biological basis, but significance unclear
- No robust data suggesting a biological basis for association


6. There are both molecular and antigenic similarities and differences between A/NJ/76 (H1N1) and 2009 A/H1N1 viruses

- A/NJ/76 (HswN1): “classical” swine influenza virus
  - All gene segments derived from viruses since 1930
- 2009 A/H1N1: novel combination of gene segments
  - 6 genes – “triple reassortant”; gene segments from swine H1N1, North American avian and human H3N2
  - NA, M – Eurasian lineage of Hsw1N1 viruses
  - HA antigenically and genetically different from A/NJ/76
- Biological properties of 2009 A/H1N1 HA and NA not fully characterized
Conclusions (1)

• A/NJ/76 (H1N1) influenza vaccine associated with increased risk of GBS in adults 6 - 8 weeks following vaccine in US civilians
  • Reasons unknown
  • No clear biological explanation

• Data on risk of GBS following other swine-antigen containing vaccines too limited to allow for conclusions

• Most data suggest little or no risk of GBS following subsequent influenza vaccines

• A/NJ/76 (H1N1) and 2009 A(H1N1) viruses differ virologically and antigenically
  • Without biological underpinning for 1976 event, unclear what significance any similarities might have on risk of vaccine

Conclusions (2)

• 1976: No significant influenza disease

• 2009: Already associated with morbidity and mortality
  • Future epidemiology, potential virulence unknown

• Risk in 1976 may have been acceptable in the setting of significant influenza-associated disease
Acknowledgments

- John D Grabenstein, RPh, PhD Col (ret) USA; Senior Director, Adult Vaccine Medical Affairs, Merck Vaccines & Infectious Diseases.
- Philip K. Russell, M.D. Major General (ret) USA
- Teresa Hammett, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention
- Dr. Cathy Parker, Biologics and Genetic Therapies Directorate Health Canada
- Dr. Mair Powell, Medicines and Healthcare products Regulatory Agency, United Kingdom of Great Britain & Northern Ireland
- Dr. Bettie Voordouw, Medicines Evaluation Board, Netherlands.

Additional Slides
GBS and Influenza Illness

- Case reports of GBS following influenza / ILI
- No substantial evidence of strong association
  - No seasonal pattern of GBS
  - No increase in GBS following large epidemics
- Several reports suggest risk, but data conflicting

Vaccine-Associated Neurologic Disease

- Neurologic AE
- Neurotropic
  - Central Nervous System
- Post-Immunization Immune-Mediated
  - Central Nervous System
- “Idiosyncratic”
  - Peripheral Nervous System
“Phylogeny” of GBSs

Guillain-Barré Syndromes

Acute Inflammatory Demyelinating Type (AIDP)
(Secondary axonal Degeneration)

Acute motor axonal Type (AMAN)

Fisher syndrome

Acute motor and Sensory axonal type (AMSAN)

CDC

CDC
Guillain-Barré Syndrome

- Acute inflammatory demyelinating polyradiculopathy—most common form of GBS in North America, Europe
  - Primarily axonal form more common in developing world
- Incidence 0.5 – 4 / 100,000, depending on study design; incidence increases with age
- Demyelination > axonal damage; cross-reactive epitopes on peripheral myelin sheath or axons
  - Various structural glycoproteins on myelin / axons induce antigenic response
- Antecedent viral-like illness or immunization reported in over 2/3

GBS

- Acute – subacute onset of weakness– evolve over days to weeks
  - Most– maximal deficit within 2 weeks
  - Hypo- or areflexia
- “Ascending” weakness—legs to arms; generally symmetric
- Sensory abnormalities
  - Ascending pain or dysesthesias
  - Objective numbness generally absent
- Autonomic dysfunction
  - Tachy / bradycardia, hypotension, arrhythmias
- Cytoalbuminologic dissociation – elevated CSF protein in absence of pleocytosis
- Characteristic electrophysiologic profile – reduced conduction velocities and decreased amplitudes indicative of demyelination
- Fisher Syndrome: “ataxia, areflexia, ophthalmoplegia”
**GBS and Glycoconjugate Antibodies**

- Gangliosides: glycosphingolipids in plasma membrane of tissues
  - Major surface molecules of PNS & CNS tissues
- Strong association of antiganglioside antibodies with GBS; thought to play a role in pathogenesis
  - Anti-GM1: AMAN
  - Anti-GQ1b: FS
- Natural infection with certain serotypes of *Campylobacter jejuni* associated with GBS
  - Cross-reactive antibodies to gangliosides and *C. jejuni* lipopolysaccharide moieties
  - Biological plausibility?

**GBS**

- Outcome generally favorable; complete recovery with or without treatment
  - Advanced age, mechanical ventilation associated with poorer outcome
- Treatment modifies disease progression and outcome
  - Intravenous immune globulin (IVIG)
  - Plasmapheresis
  - Corticosteroids contraindicated
GBS vs. CIDP

<table>
<thead>
<tr>
<th></th>
<th>GBS</th>
<th>CIDP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td>AIDP: Variable</td>
<td>No antibodies</td>
</tr>
<tr>
<td></td>
<td>AMAN: GM1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FS: GQ1b</td>
<td></td>
</tr>
<tr>
<td>Antecedent event</td>
<td>70%</td>
<td>None</td>
</tr>
<tr>
<td>Course</td>
<td>Monophasic</td>
<td>Relapsing / remitting</td>
</tr>
<tr>
<td>Treatment</td>
<td>IVIG, PLEX</td>
<td>Steroids, IVIG, PLEX</td>
</tr>
<tr>
<td>Pathology</td>
<td>Axonal and demyelinating</td>
<td>Demyelinating</td>
</tr>
</tbody>
</table>

Differentiation between GBS and CIDP requires longitudinal follow-up to identify relapses and remissions

GBS and Vaccines

Influenza

- 1976 swine influenza: small but significant risk for GBS (1 additional case / 100,000 vaccinees) 1 – 6 weeks post-immunization
  - IOM: “evidence favors a causal association...”
- Association between other influenza vaccine formulations and immunizations less clear
  - 19 well-designed, controlled studies in the literature between 1977 and 2009
  - 2 (Lasky et al., 1998 [flu]; Kinnunen et al., 1989 [OPV]) suggest slightly increased risk...(maximal odds ratio 1.7)
- No clear, consistent association
- Biological data: swine influenza vaccine, but also other formulations, induces anti-myelin ganglioside antibodies in mice (Nachamkin et al. 2008)
  - Provides biological basis, but significance unclear